Department of Medical Microbiology (Schering AG)

The Department of Medical Microbiology at Schering AG was a pivotal division within the company, focusing on the research and development of microbiological solutions in the medical field. This department played a crucial role in advancing the understanding of infectious diseases and the development of antimicrobial agents.

History

The Department of Medical Microbiology was established as part of Schering AG's commitment to innovation in the pharmaceutical industry. Schering AG, a German pharmaceutical company, was founded in 1851 and became known for its contributions to the development of various medical treatments.

Early Developments

In its early years, the department concentrated on the study of bacterial pathogens and the development of antibiotics. This was a period marked by significant advancements in microbiology, with the discovery of penicillin and other antibiotics revolutionizing the treatment of bacterial infections.

Expansion and Research Focus

During the mid-20th century, the department expanded its research focus to include virology and immunology. This expansion was in response to the growing understanding of viral diseases and the need for effective vaccines and antiviral drugs.

Research Contributions

The Department of Medical Microbiology at Schering AG made several notable contributions to the field of medical microbiology.

Antibiotic Development

The department was instrumental in the development of new antibiotics that were effective against a broad range of bacterial infections. These antibiotics helped to combat resistant strains of bacteria and were crucial in the treatment of infectious diseases.

Vaccine Research

In addition to antibiotics, the department also focused on vaccine research. This included the development of vaccines for viral infections, which were becoming increasingly important as new viruses emerged.

Innovations in Diagnostic Techniques

The department also contributed to the development of innovative diagnostic techniques that improved the detection and identification of pathogens. These techniques enhanced the ability of healthcare providers to diagnose infections accurately and promptly.

Impact on Public Health

The work of the Department of Medical Microbiology had a significant impact on public health. By developing effective treatments and preventive measures, the department helped to reduce the incidence and severity of infectious diseases worldwide.

Closure and Legacy

The department was eventually closed following the merger of Schering AG with Bayer AG in 2006. Despite its closure, the legacy of the department lives on through its contributions to medical science and its impact on the treatment of infectious diseases.

The Bayer Schering Pharma building in Berlin, 2008

Related Pages

• Schering AG
• Bayer AG
• Antibiotics
• Vaccines
• Microbiology